Skip to main content

Bacteriophage inhibition of antibiotic-resistant pathogenic microbes and founding for novel therapeutic strategies

Project description

Profiling a mysterious natural 'warrior' to counter antimicrobial resistance

Complex battles between single-celled organisms – bacteria and the viruses that 'eat' them (bacteriophages) – take place all around us largely unbeknownst to the average person. As antimicrobial resistance creates an ever-growing challenge to public health, harnessing these natural bacterial killers is a promising route to new therapeutics. The problem is that, although bacteriophages are the most abundant organisms in the biosphere, we have isolated very few of them and have very little idea about how they work. All that is about to change thanks to the EU-funded PHARMS project. Scientists have ambitious plans to find all possible phages of a resistant bacterial isolate, characterise the mechanisms of action, and use the new-found knowledge to design a toolkit of phage-based therapies.

Field of science

  • /medical and health sciences/health sciences/infectious disease
  • /natural sciences/biological sciences/synthetic biology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/antibiotic resistance

Call for proposal

ERC-2018-STG
See other projects for this call

Funding Scheme

ERC-STG - Starting Grant

Host institution

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Address
Ingolstadter Landstrasse 1
85764 Neuherberg
Germany
Activity type
Research Organisations
EU contribution
€ 1 499 650

Beneficiaries (1)

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany
EU contribution
€ 1 499 650
Address
Ingolstadter Landstrasse 1
85764 Neuherberg
Activity type
Research Organisations